FDA Approves Daily Pill for Advanced Breast Cancer

The U.S. Food and Drug Administration approved a new oral medication on Monday for adults with advanced breast cancer whose tumors have become resistant to existing treatments. The drug, which is taken once daily, is indicated for patients whose disease has progressed after standard endocrine or chemotherapy regimens and who lack other approved options. The approval follows a pivotal phase‑3 study that enrolled 520 participants across 12 countries, demonstrating a statistically significant improvement in progression‑free survival compared with placebo.

In the trial, patients receiving the new therapy experienced a median progression‑free survival of 9.2 months versus 5.6 months for the control group, with an overall response rate of 28% versus 12%. Common adverse events included nausea, fatigue, and mild transaminase elevations, all of which were manageable with dose adjustments. The drug’s mechanism of action involves inhibition of a key signaling pathway that drives tumor growth in hormone‑receptor‑positive and HER2‑negative subtypes, offering a targeted approach when conventional therapies fail.

This approval expands the therapeutic landscape for advanced breast cancer, providing clinicians with a new option for patients who have exhausted other lines of treatment. The FDA’s decision underscores the continued need for innovative therapies that address drug resistance and improve outcomes for women facing this challenging disease.